Invitrogen™ Erenumab Recombinant Human Monoclonal Antibody

Catalog No.	Quantity
PIMA542108	100 μg

Catalog No. PIMA542108

Supplier: Invitrogen™ MA542108

Description

Human Recombinant Monoclonal Antibody

Endotoxin level < 0.01EU/μg by LAL method Use a manual defrost freezer and avoid repeated freeze thaw cycles. Store at 2 to 8 °C for one week. Store at -20 to -80 °C for twelve months from the date of receipt.

Erenumab (AMG-334) (INN; trade name Aimovig) is a human monoclonal antibody designed specifically to bind and antagonize the calcitonin gene-related peptide receptor (CGRPR) as a means to prevent migraines. Aimovig, as released and marketed by Novartis and Amgen, is in fact a novel therapeutic approach as the first and only FDA approved treatment specifically developed to prevent migraine by blocking the CGRP receptor, which is believed to play a critical role in migraine .

Specifications

• Antigen: Erenumab
• Applications: ELISA, SDS-Page
• Classification: Recombinant Monoclonal
• Concentration: 1.12 mg/mL
• Conjugate: Unconjugated
• Formulation: PBS with no preservative; pH 7.4
• Gene Alias: AMG 334; erenumab-aooe
• Host Species: Human
• Immunogen: Human CALCRL/CGRP-R.
• Purification Method: Protein A/G
• Quantity: 100 μg
• Regulatory Status: RUO
• Primary or Secondary: Primary
• Target Species: Human
• Content And Storage: -20°C, Avoid Freeze/Thaw Cycles
• Product Type: Antibody
• Form: Liquid
• Isotype: IgG2 λ
• Target Molecule: Chemical